View More View Less
  • 1 Onkoradiológiai Központ, Fővárosi Önkormányzat Uzsoki utcai Kórháza, 1145, Budapest, Uzsoki u. 29–41.
  • 2 Onkológiai Gondozó, Bajcsy-Zsilinszky Kórház Rendelőintézet, Budapest
Restricted access

Absztrakt

A távoli áttétes, IV. stádiumú kolorektális rák (metastatic colorectal cancer, mCRC) gyógyszeres kezelése jelentős fejlődésen ment át az utóbbi években. A standard fluorouracil/folinát-kezelések mellett új hatóanyagok jelentek meg (oxaliplatin, irinotecan), de legújabban a “célzott” biológiai terápiás szerek (bevacizumab, cetuximab, panitumumab) is bizonyították hatékonyságukat. A közlemény összefoglalja az mCRC első választású kezelésének fejlődését.

  • 1. RG Amado M Wolf M Peeters 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634.

    • Search Google Scholar
    • Export Citation
  • 2. André T , Tabernero J, Van Cutsem, et al. Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Final results. 2007 Gastrointestinal Cancers Symposium, 2007.

    • Search Google Scholar
    • Export Citation
  • 3. H-T Arkenau S Schmoll A Kubicka 2005 Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis Proc ASCO 23 247s.

    • Search Google Scholar
    • Export Citation
  • 4. SR Berry E Van Cutsem A Kretzschmar 2008 Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT J Clin Oncol 26 15 Suppl 4025.

    • Search Google Scholar
    • Export Citation
  • 5. J Cassidy J Tabernero C Twelves 2004 XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 2084 2091.

    • Search Google Scholar
    • Export Citation
  • 6. KY Chung J Shia NE Kemeny 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunochemistry J Clin Oncol 23 1803 1810.

    • Search Google Scholar
    • Export Citation
  • 7. ClinicalTrials.gov. Cetuximab and/or bevacizumab combined with combination chemotherapy in treating patients with metastatic colorectal cancer. http://www.clinicaltrials.gov/ct/show/NCT00265850?order=1.

    • Search Google Scholar
    • Export Citation
  • 8. D Cunningham B Sirohi A Pluzanska 2009 Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer Ann Oncol 20 244 250.

    • Search Google Scholar
    • Export Citation
  • 9. D Cunningham Y Humblet S Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345.

    • Search Google Scholar
    • Export Citation
  • 10. A de Gramont A Figer M Seymour 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947.

    • Search Google Scholar
    • Export Citation
  • 11. F Di Fiore F Blanchard F Charbonnier 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 1166 1169.

    • Search Google Scholar
    • Export Citation
  • 12. F Di Nicolantonio M Martini F Molinari 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712.

    • Search Google Scholar
    • Export Citation
  • 13. JY Douillard D Cunningham AD Roth 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047.

    • Search Google Scholar
    • Export Citation
  • 14. A Falcone S Ricci I Brunetti 2007 Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 1670 1676.

    • Search Google Scholar
    • Export Citation
  • 15. Folprecht G , Gruenberger T, Hartmann JT, et al. Randomized multicenter study of cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-study). ESMO 2008, Abstr 510PD.

    • Search Google Scholar
    • Export Citation
  • 16. M Frattini P Saletti E Romagnani 2007 PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 1139 1145.

    • Search Google Scholar
    • Export Citation
  • 17. CS Fuchs J Marshall EP Mitchell 2007 Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: Updated efficacy data J Clin Oncol 25 18 Suppl 4027.

    • Search Google Scholar
    • Export Citation
  • 18. RM Goldberg DJ Sargent RF Morton 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30.

    • Search Google Scholar
    • Export Citation
  • 19. A Grothey D Sargent RM Goldberg HJ Schmoll 2004 Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leukovorin, irinotecan and oxaliplatin in the course of treatment J Clin Oncol 22 1209 1214.

    • Search Google Scholar
    • Export Citation
  • 20. A Grothey MM Sugrue DM Purdie 2008 Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE) J Clin Oncol 20 5326 5334.

    • Search Google Scholar
    • Export Citation
  • 21. B Gruenberger D Tamandl J Schueller 2008 Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 10 1830 1835.

    • Search Google Scholar
    • Export Citation
  • 22. Hecht JR , Chidiac T, Mitchell E, et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (bev) for metastatic colorectal cancer (mCRC). World Gastrointestinal Cancer Congress Meeting, 2008.

    • Search Google Scholar
    • Export Citation
  • 23. Hecht JR , Mitchell E, Chidiac T, et al. An updated analysis of the safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized controlled trial (PACCE). 2008 Gastrointestinal Cancers Symposium, 2008.

    • Search Google Scholar
    • Export Citation
  • 24. E Hedrick M Kozloff J Hainsworth 2006 Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE) J Clin Oncol 24 18 Suppl 3536.

    • Search Google Scholar
    • Export Citation
  • 25. HS Hochster LL Hart RK Ramanathan 2008 Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer. Results of the TREE study J Clin Oncol 26 3523 3529.

    • Search Google Scholar
    • Export Citation
  • 26. H Hurwitz L Fehrenbacher W Novotny 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342.

    • Search Google Scholar
    • Export Citation
  • 27. HI Hurwitz J Yi W Ince 2009 The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 22 28.

    • Search Google Scholar
    • Export Citation
  • 28. CS Karapetis S Khambata-Ford DJ Jonker 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765.

    • Search Google Scholar
    • Export Citation
  • 29. CH Köhne G Folprecht 2006 On prejudice and facts and choices Ann Oncol 17 185 187.

  • 30. CH Köhne E van Cutsem J Wils 2005 Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986 J Clin Oncol 23 4856 4865.

    • Search Google Scholar
    • Export Citation
  • 31. M Koopman NF Antonioni J Douma 2007 Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial Lancet 370 135 142.

    • Search Google Scholar
    • Export Citation
  • 32. L Lakatos PL Lakatos 2005 A colorectalis daganatok korszerű kezelése LAM 15 177 186.

  • 33. A Liévre JB Bachet V Boige 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379.

    • Search Google Scholar
    • Export Citation
  • 34. A Liévre JB Bachet D Le Corre 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995.

    • Search Google Scholar
    • Export Citation
  • 35. RJ Mayer 2009 Targeted therapy for advanced colorectal cancer – more is not always better N Engl J Med 2009 360 623 625.

  • 36. Meta-analysis Group in Cancer 1998 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 301 308.

    • Search Google Scholar
    • Export Citation
  • 37. BH O'Neil RM Goldberg 2008 Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials Oncologist 13 1074 1083.

    • Search Google Scholar
    • Export Citation
  • 38. YZ Patt J Liebmann D Diamandidis 2004 Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial J Clin Oncol 22 Suppl 14S.

    • Search Google Scholar
    • Export Citation
  • 39. N Personeni S Fieuws H Piessevaux 2008 Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study Clin Cancer Res 14 5869 5876.

    • Search Google Scholar
    • Export Citation
  • 40. R Petrioli L Paolelli S Marsili 2006 FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer Oncology 70 345 350.

    • Search Google Scholar
    • Export Citation
  • 41. CJ Punt J Tol CJ Rodenburg 2008 Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) J Clin Oncol 26 15 Suppl LBA4011.

    • Search Google Scholar
    • Export Citation
  • 42. P Rougier E Van Cutsem E Bajetta 1998 Randomised trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1407 1412.

    • Search Google Scholar
    • Export Citation
  • 43. B Sakar M Gumus M Basaran 2007 XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer Oncology 73 298 304.

  • 44. LB Saltz S Clarke E Diaz-Rubio 2007 Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (mCRC) J Clin Oncol 25 18 Suppl 4028.

    • Search Google Scholar
    • Export Citation
  • 45. H Sanoff DJ Sargent ME Campbell 2007 N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC) J Clin Oncol 25 4067.

    • Search Google Scholar
    • Export Citation
  • 46. A Sartire-Bianchi M Moroni S Veronese 2007 Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab J Clin Oncol 25 3238 3245.

    • Search Google Scholar
    • Export Citation
  • 47. M Saunders T Iveson 2006 Management of advanced colorectal cancer: state of the art Br J Cancer 95 131 138.

  • 48. MT Seymour TS Maughan JA Ledermann 2007 Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 143 152.

    • Search Google Scholar
    • Export Citation
  • 49. J Souglakos N Androulakis K Syrigos 2006 FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 798 805.

    • Search Google Scholar
    • Export Citation
  • 50. P Thirion S Michelis JP Pignon 2004 Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated metaanalysis J Clin Oncol 22 3766 3775.

    • Search Google Scholar
    • Export Citation
  • 51. J Tol M Koopman A Cats 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 563 572.

  • 52. C Tournigand T André E Achille 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study J Clin Oncol 22 229 237.

    • Search Google Scholar
    • Export Citation
  • 53. C Tournigand A Cervantes A Figer 2006 OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study J Clin Oncol 24 394 400.

    • Search Google Scholar
    • Export Citation
  • 54. C Twelves A Wong MP Nowacki 2005 Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2696 2704.

  • 55. E Van Cutsem PM Hoff P Haper 2004 Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 1190 1197.

    • Search Google Scholar
    • Export Citation
  • 56. E Van Cutsem M Nowacki I Lang 2007 Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial J Clin Oncol 25 18 Suppl 4000.

    • Search Google Scholar
    • Export Citation
  • 57. E Van Cutsem I Lang G D'Haens 2008 KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience J Clin Oncol 26 15 Suppl 2.

    • Search Google Scholar
    • Export Citation
  • 58. S Velho C Oliviera A Ferreira 2005 The prevalence of PIK3CA mutations in gastric and colon cancer Eur J Cancer 41 1649 1654.

  • 59. A Venook D Niedzwiecki D Hollis 2006 Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results J Clin Oncol 24 18 Suppl 3509.

    • Search Google Scholar
    • Export Citation
  • 60. R Wong D Cunningham 2008 Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies J Clin Oncol 26 5668 5670.

    • Search Google Scholar
    • Export Citation
  • 61. E Yaman A Uner O Er 2007 Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer Med Oncol 24 431 435.

    • Search Google Scholar
    • Export Citation